{"id":180234,"date":"2026-02-10T02:37:42","date_gmt":"2026-02-10T07:37:42","guid":{"rendered":"https:\/\/alphastreet.com\/india\/?p=180234"},"modified":"2026-02-10T02:37:44","modified_gmt":"2026-02-10T07:37:44","slug":"aurobindo-pharma-limited-posts-q3-fy26-revenue-growth-on-europe-strength-margins-stable","status":"publish","type":"post","link":"https:\/\/alphastreet.com\/india\/aurobindo-pharma-limited-posts-q3-fy26-revenue-growth-on-europe-strength-margins-stable\/","title":{"rendered":"Aurobindo Pharma Limited posts Q3 FY26 revenue growth on Europe strength; margins stable"},"content":{"rendered":"\n

Aurobindo Pharma Limited (NSE: AUROPHARMA, BSE: 524804)<\/strong> reported higher revenue and profit for the quarter ended Dec. 31, 2025, supported by strong growth in Europe and stable performance in the U.S. base business, according to the company\u2019s revised Q3 FY26 investor presentation used for its analyst call.<\/p>\n\n\n\n

Q3 FY26 financial performance<\/h2>\n\n\n\n

Revenue from operations rose 8.4% year on year to \u20b98,646 crore<\/strong> in Q3 FY26. Growth was driven by Europe and ARV businesses, while the U.S. base business remained stable despite lower sales of transient products.<\/p>\n\n\n\n

EBITDA increased 9.0% to \u20b91,773 crore<\/strong>, with the EBITDA margin at 20.5%<\/strong>, broadly stable year on year. Net profit attributable to owners of the company rose 7.6% to \u20b9910 crore<\/strong>. Reported EPS increased to \u20b915.67<\/strong> from \u20b914.56 a year earlier.<\/p>\n\n\n\n

Gross margin improved by 129 basis points to 59.7%<\/strong>, reflecting stable product mix and operating efficiencies. Finance costs declined year on year, while depreciation rose due to ongoing investments in capacity and compliance.<\/p>\n\n\n\n

Regional and business mix<\/h2>\n\n\n\n

The U.S. formulations business<\/strong> (excluding Puerto Rico) generated $420 million<\/strong> in Q3 FY26 revenue, accounting for 43.2% of consolidated revenue<\/strong>. The company launched nine products<\/strong> in the U.S. during the quarter and received approvals for seven ANDAs<\/strong>, including two final approvals previously granted tentative status.<\/p>\n\n\n\n

Europe revenue grew 27.4% year on year to \u20b92,703 crore<\/strong>, driven by strong performance across key markets. Growth markets revenue declined 0.9% year on year<\/strong>, reflecting a softer performance in Indonesia, partly offset by growth in other markets.<\/p>\n\n\n\n

The ARV business<\/strong> recorded 22.4% year-on-year growth to \u20b9376 crore<\/strong>, aided by additional business opportunities. API revenue declined 4.3% year on year to \u20b9963 crore<\/strong>, impacted by market conditions and pricing pressure.<\/p>\n\n\n\n

Cash flow, capex and balance sheet<\/h2>\n\n\n\n

The company generated free cash flow of $118 million<\/strong> during the quarter. Net capex of about $79 million<\/strong> was deployed toward capability enhancements and new business development.<\/p>\n\n\n\n

As of Dec. 31, 2025, net cash (including investments) stood at about $287 million<\/strong>, or about $251 million after accounting for cash appropriated for the Khandelwal Labs acquisition<\/strong>. The company maintained a net cash position, reflecting strong operating cash generation and disciplined capital allocation.<\/p>\n\n\n\n

R&D and pipeline<\/h2>\n\n\n\n

Total R&D spend for the quarter was \u20b9409 crore<\/strong>, or 4.7% of sales<\/strong>, focused on biosimilars and specialty products. The company highlighted progress at its biosimilars arm CuraTeQ Biologics, with approvals in regulated markets and multiple filings under review.<\/p>\n\n\n\n

Two biosimilars, BP16 (denosumab)<\/strong> and BP11 (omalizumab)<\/strong>, are planned for regulatory submissions in the U.S. and Europe in 2026. Management said the biosimilars portfolio of 15 products<\/strong> targets large biologics losing patent protection over 2028\u20132035, with a multi-billion-dollar addressable market.<\/p>\n\n\n\n

Regulatory filings and product pipeline<\/h2>\n\n\n\n

As of Dec. 31, 2025, Aurobindo had 879 U.S. ANDAs filed<\/strong>, with 719 final approvals<\/strong>, 31 tentative approvals<\/strong>, and 129 under review<\/strong>. The global filings footprint continued to expand across Europe and other markets, supporting medium-term growth visibility.<\/p>\n\n\n\n

Summary<\/h2>\n\n\n\n

Aurobindo Pharma delivered steady Q3 FY26 growth, with Europe and ARV businesses driving revenue while U.S. base sales remained stable. Margins were supported by operating efficiencies, and the company maintained a net cash position. Progress in biosimilars, ongoing product launches, and a strong regulatory pipeline provide visibility into future growth, even as pricing pressure persists in APIs and transient U.S. products.
<\/p>\n","protected":false},"excerpt":{"rendered":"

Aurobindo Pharma Limited (NSE: AUROPHARMA, BSE: 524804) reported higher revenue and profit for the quarter ended Dec. 31, 2025, supported by strong growth in Europe and stable performance in the U.S. base business, according to the company\u2019s revised Q3 FY26 investor presentation used for its analyst call. Q3 FY26 financial performance Revenue from operations rose […]<\/p>\n","protected":false},"author":2409,"featured_media":0,"comment_status":"open","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"jetpack_post_was_ever_published":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[5],"tags":[16102,16097,16093,16099,16095,14565,16101,16094,16096,16098,15062,10089,14561,16100],"class_list":["post-180234","post","type-post","status-publish","format-standard","hentry","category-latest","tag-anda-approvals","tag-arv-business","tag-aurobindo-pharma","tag-biosimilars-pipeline","tag-bse-524804","tag-ebitda-margin","tag-europe-business-growth","tag-net-profit-growth","tag-nse-auropharma","tag-pharmaceutical-industry","tag-q3-fy26-results","tag-quarterly-earnings","tag-revenue-growth","tag-us-formulations"],"jetpack_publicize_connections":[],"jetpack_featured_media_url":"","jetpack_likes_enabled":false,"jetpack-related-posts":[{"id":140759,"url":"https:\/\/alphastreet.com\/india\/aurobindo-pharma-limited-nse-auropharma-q3-fy23-results-out-total-income-rises-7-yoy\/","url_meta":{"origin":180234,"position":0},"title":"Aurobindo Pharma Limited (NSE: AUROPHARMA): Q3 FY23 Results Out; Total Income Rises 7% YoY","author":"Divyansh_Kasana","date":"February 9, 2023","format":false,"excerpt":"Aurobindo Pharma Limited (NSE: AUROPHARMA) is a pharmaceutical company based in Hyderabad, India. The company was founded in 1986 and has since grown to become one of the largest pharmaceutical companies in India, with a presence in over 150 countries. Aurobindo Pharma produces a wide range of generic and specialty\u2026","rel":"","context":"In "AlphaGraphs"","block_context":{"text":"AlphaGraphs","link":"https:\/\/alphastreet.com\/india\/category\/infographics\/"},"img":{"alt_text":"","src":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2023\/02\/b7778d7c-e8b5-4ee8-8702-740018666b7d.png?resize=350%2C200&ssl=1","width":350,"height":200,"srcset":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2023\/02\/b7778d7c-e8b5-4ee8-8702-740018666b7d.png?resize=350%2C200&ssl=1 1x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2023\/02\/b7778d7c-e8b5-4ee8-8702-740018666b7d.png?resize=525%2C300&ssl=1 1.5x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2023\/02\/b7778d7c-e8b5-4ee8-8702-740018666b7d.png?resize=700%2C400&ssl=1 2x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2023\/02\/b7778d7c-e8b5-4ee8-8702-740018666b7d.png?resize=1050%2C600&ssl=1 3x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2023\/02\/b7778d7c-e8b5-4ee8-8702-740018666b7d.png?resize=1400%2C800&ssl=1 4x"},"classes":[]},{"id":128324,"url":"https:\/\/alphastreet.com\/india\/aurobindo-pharma-q3-fy-2022-research-tear-sheet\/","url_meta":{"origin":180234,"position":1},"title":"Aurobindo Pharma Q3 FY 2022 Research Tear Sheet","author":"sreerupa","date":"March 23, 2022","format":false,"excerpt":"Aurobindo Pharma Limited\u00a0is an Indian\u00a0pharmaceutical company. It is based in \u00a0HITEC City,\u00a0Hyderabad, India. It was incorporated in 1986. The pharmaceutical products include generic drugs, over-the-counter drugs, vaccines, diagnostics, contact lenses and animal health. The company markets its products in more 125+ countries by Pfizer and AstraZeneca plc. The shares are\u2026","rel":"","context":"In "Research Summary"","block_context":{"text":"Research Summary","link":"https:\/\/alphastreet.com\/india\/category\/research-summary\/"},"img":{"alt_text":"","src":"","width":0,"height":0},"classes":[]},{"id":156074,"url":"https:\/\/alphastreet.com\/india\/aurobindo-pharma-limited-q2-fy24-earnings-conference-call-insights\/","url_meta":{"origin":180234,"position":2},"title":"Aurobindo Pharma Limited Q2 FY24 Earnings Conference Call Insights","author":"Praveen","date":"November 10, 2023","format":false,"excerpt":"Key highlights from Aurobindo Pharma Limited (AUROPHARMA) Q2 FY24 Earnings Concall Revenue Growth Revenue grew 25.8% year-on-year to INR7,219 crores, driven by growth across formulations, APIs, and geographies. Formulations revenue, excluding Puerto Rico, grew 29% YoY to INR5,968 crores. US formulations revenue, without Puerto Rico, grew 35.7% year-on-year to INR3,385\u2026","rel":"","context":"In "Concall Highlights"","block_context":{"text":"Concall Highlights","link":"https:\/\/alphastreet.com\/india\/category\/earnings-call-highlights\/"},"img":{"alt_text":"","src":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2023\/10\/CC_Image_1.jpg?resize=350%2C200&ssl=1","width":350,"height":200,"srcset":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2023\/10\/CC_Image_1.jpg?resize=350%2C200&ssl=1 1x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2023\/10\/CC_Image_1.jpg?resize=525%2C300&ssl=1 1.5x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2023\/10\/CC_Image_1.jpg?resize=700%2C400&ssl=1 2x"},"classes":[]},{"id":179824,"url":"https:\/\/alphastreet.com\/india\/marksans-pharma-reports-q3fy26-with-revenue-growth-and-ebitda-margin-expansion\/","url_meta":{"origin":180234,"position":3},"title":"Marksans Pharma Reports Q3FY26 with Revenue Growth and EBITDA Margin Expansion","author":"Staff Correspondent","date":"February 6, 2026","format":false,"excerpt":"About Marksans Pharma Limited Marksans Pharma Limited (NSE: MARKSANS) is an Indian pharmaceutical company headquartered in Mumbai, India, founded in 1992. It specializes in the research, development, manufacturing and marketing of pharmaceutical formulations, offering both over-the-counter (OTC) and prescription medicines across various therapeutic areas such as pain management, cardiovascular health,\u2026","rel":"","context":"In "Analysis"","block_context":{"text":"Analysis","link":"https:\/\/alphastreet.com\/india\/category\/stock-analysis\/"},"img":{"alt_text":"","src":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2021\/11\/Earnings-Coverage.jpg?resize=350%2C200&ssl=1","width":350,"height":200,"srcset":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2021\/11\/Earnings-Coverage.jpg?resize=350%2C200&ssl=1 1x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2021\/11\/Earnings-Coverage.jpg?resize=525%2C300&ssl=1 1.5x"},"classes":[]},{"id":133199,"url":"https:\/\/alphastreet.com\/india\/aurobindo-pharma-limited-q1-fy-2023-research-tear-sheet\/","url_meta":{"origin":180234,"position":4},"title":"Aurobindo Pharma Limited Q1 FY 2023 Research Tear Sheet","author":"sreerupa","date":"August 15, 2022","format":false,"excerpt":"Stock Data Ticker: AUROPHARMA Exchange :NSE and BSE Industry: Automobile Price Performance Last 7 days\u00a0\u00a0\u00a0 4.36% YTD\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 -19.19% Last 12 months\u00a0\u00a0\u00a0\u00a0 -28.17% It will be beneficial to invest in the stocks of Aurobindo Pharma. The company enjoys a \u00a0healthy\u00a0ROE of\u00a021.49% ROE which is an\u00a0 important financial parameter. The company has\u2026","rel":"","context":"In "Analysis"","block_context":{"text":"Analysis","link":"https:\/\/alphastreet.com\/india\/category\/stock-analysis\/"},"img":{"alt_text":"Research Summary","src":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2020\/04\/Research-summary.jpg?resize=350%2C200&ssl=1","width":350,"height":200,"srcset":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2020\/04\/Research-summary.jpg?resize=350%2C200&ssl=1 1x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2020\/04\/Research-summary.jpg?resize=525%2C300&ssl=1 1.5x"},"classes":[]},{"id":172164,"url":"https:\/\/alphastreet.com\/india\/aurobindo-pharma-q2-fy26-earnings-results\/","url_meta":{"origin":180234,"position":5},"title":"Aurobindo Pharma Q2 FY26 Earnings Results","author":"Divyansh_Kasana","date":"November 6, 2025","format":false,"excerpt":"Aurobindo Pharma Ltd, a leading pharmaceutical company focused on active pharmaceutical ingredients and generic pharmaceuticals, reported a steady Q2FY26 financial performance with revenues rising 6.3% year-on-year to \u20b98,286 crore. Consolidated net profit increased by 3.8% to \u20b9848 crore, reflecting resilience in key markets such as the US and Europe. Key\u2026","rel":"","context":"In "AlphaGraphs"","block_context":{"text":"AlphaGraphs","link":"https:\/\/alphastreet.com\/india\/category\/infographics\/"},"img":{"alt_text":"Q2 FY26","src":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/11\/auro.png?resize=350%2C200&ssl=1","width":350,"height":200,"srcset":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/11\/auro.png?resize=350%2C200&ssl=1 1x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/11\/auro.png?resize=525%2C300&ssl=1 1.5x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/11\/auro.png?resize=700%2C400&ssl=1 2x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/11\/auro.png?resize=1050%2C600&ssl=1 3x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/11\/auro.png?resize=1400%2C800&ssl=1 4x"},"classes":[]}],"jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/posts\/180234","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/users\/2409"}],"replies":[{"embeddable":true,"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/comments?post=180234"}],"version-history":[{"count":1,"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/posts\/180234\/revisions"}],"predecessor-version":[{"id":180235,"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/posts\/180234\/revisions\/180235"}],"wp:attachment":[{"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/media?parent=180234"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/categories?post=180234"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/tags?post=180234"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}